|
|
|
|
ACC: Fibrate+statin therapy do not lower CV events in adult diabetics
ATLANTATreating multiple blood lipids with combination drug therapy of a fibrate and a statin did not reduce the combined risk of cardiovascular disease events more than treatment with statin alone, according to the ACCORD trial presented today at the late...
|
|
|
ACC: Intensive BP lowering does not reduce CV events in adult diabetics
ATLANTALowering blood pressure to below currently recommended levels did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular events,...
|
|
|
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the ' ' trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA?(saxagliptin), a...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
PRINCETON, N.J.& WILMINGTON, Del.--(HSMN NewsFeed)--Bristol-Myers Squibb Company (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) today announced the commencement of the 'Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes ...
|
|
|
Bristol-Myers Squibb and AstraZeneca Initiate the Saxagliptin Assessment of Vascular Outcomes in Patients with Diabetes Mellitus
Bristol-Myers Squibb Company and AstraZeneca have announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo...
|
|
|
Bristol-Myers Squibb and AstraZeneca Initiate the Saxagliptin Ass...
Company: Bristol-Myers Squibb Co.(BMY) Bristol-Myers Squibb Company and AstraZeneca have announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a...
|
|
|
Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus
Masuda T et al.Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus.
|
|
|
Stem Cell Treatment for Diabetes Mellitus
Stem cell therapy has the potential to revolutionize the treatment of a variety of human conditions.FOR IMMEDIATE RELEASE PR Log (Press Release) Mar 11, 2010 Stem cell therapy has the potential to revolutionize the treatment of a variety of human conditions....
|
|
|
Gestational Diabetes Mellitus: NICE for the U.S.? A Comparison of the American Diabetes Association and the Am
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Gestational Diabetes Mellitus: NICE for the U.S.? A Comparison of the American Diabetes Association and the Am
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
BMS & AstraZeneca begin phase-4 trial of Saxgliptin in type-2 diabetes with cardio risk factors
Bristol-Myers Squibb Company and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo...
|
|
|
Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus
It has been proved that cilnidipine has N-type calcium channels inhibitory activity as well as L-type calcium channels and inhibits excessive release of norepinephrine from the sympathetic nerve ending.This study was undertaken to compare the efficacy of...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
BristolMyers Squibb Company and AstraZeneca announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial, a multicenter, randomized, doubleblind, placebocontrolled Phase 4 Bristol...
|
|
|
Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
BristolMyers Squibb Company and AstraZeneca announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial, a multicenter, randomized, doubleblind, placebocontrolled Phase 4 study, to...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
PRINCETON, N.J.& WILMINGTON, Del.(BUSINESS WIRE) Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes ...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
- (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo...
|
|
|
Bristol-Myers Squibb Initiates SAVOR-TIMI 53 Trial Of Onglyza
Bristol-Myers Squibb has initiated Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial (SAVOR-TIMI 53), to evaluate treatment with Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult...
|
|
|
Bristol-Myers Squibb, AstraZeneca Begin Diabetes Mellitus Trial
Bristol-Myers Squibb Company and AstraZeneca Tuesday announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
PRINCETON, N.J.& WILMINGTON, Del.-- (BUSINESS WIRE) -- (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial (SAVOR-TIMI...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
(BUSINESS WIRE) ----Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
(BUSINESS WIRE) ----Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Companies mentioned in this article: Bristol-Myers Squibb Company PRINCETON, N.J.& WILMINGTON, Del. -- (BUSINESS WIRE) -- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the Saxagliptin...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
ed in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53) PRINCETON, N.J.& WILMINGTON, Del. - (BUSINESS WIRE) - (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the 'S The objectives of the SAVOR-TIMI 53 trial...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
PRINCETON, N.J.& WILMINGTON, Del.Bristol-Myers Squibb Company (NYSE The objectives of the SAVOR-TIMI 53 trial are to test the hypothesis of whether treatment with ONGLYZA compared with placebo when added to a patients current standard of care will result...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
Let the jobs come to you!(NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the ?Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus! trial (SAVOR-TIMI 53), a multicenter, randomized,...
|
